Navigation Links
Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
Date:12/1/2011

ot be treated with Reclast.

If you have HCM, you should drink plenty of clear fluids before using ZOMETA. If you have kidney problems, tell your doctor. The risk of adverse reactions (especially related to the kidney) may be greater for you. ZOMETA treatment is not for patients with severe kidney problems. Patients with kidney problems on multiple cycles of ZOMETA or other bisphosphonates are at greater risk for further kidney problems. It is important to get your blood tests while you are receiving ZOMETA. Your doctor will monitor your kidney function before each dose. Tell your doctor if you are on other drugs, including aminoglycosides, loop diuretics, and drugs which may be harmful to the kidney.

Osteonecrosis of the jaw (ONJ) has been reported mainly in cancer patients treated with intravenous bisphosphonates, including ZOMETA. Many of these patients were also receiving anti-cancer drugs and corticosteroids, which may make it more likely to get ONJ. If you have advanced breast cancer or a type of cancer called multiple myeloma, or if you have had dental extraction, periodontal disease, local trauma, including poorly fitting dentures, you may be at greater risk of getting ONJ. Many reports of ONJ involved patients with signs of local infection, including bone/bone marrow inflammation. You should maintain good oral hygiene and have a dental examination with preventive dentistry prior to beginning ZOMETA. While on treatment, avoid invasive dental procedures, if possible, as recovery may take longer. If you develop ONJ while on bisphosphonate therapy, dental surgery may worsen the condition. If you require dental procedures, there are no data available to suggest whether stopping ZOMETA treatment reduces the risk of ONJ. A causal relationship between bisphosphonate use and ONJ has not been established. Based on your condition, your doctor will determine the treatment plan you will receive.

Do not use ZOMETA if you are pregnant or plan to becom
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
2. Genentech and Novartis Remain Image Leaders in Oncology and Hematology
3. FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD
4. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
5. With the Recent Launch of Novartiss Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
6. VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
7. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
8. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
9. Novartis Class Awarded $250 Million in Punitive Damages
10. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
11. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... July 6, 2015  Emdeon Inc. today ... definitive agreement to acquire Altegra Health, a ... that combine data aggregation and analytics with ... achieve actionable insights and improved management for ... Health,s risk adjustment and quality analytics and ...
(Date:7/6/2015)... , July 6, 2015 ImmunoCellular Therapeutics, Ltd. ... an agreement with Novella Clinical (Novella), to ... patients with newly diagnosed glioblastoma. Novella is a full-service, ... to small to mid-sized oncology companies. The ICT-107 phase ... the US, Europe and ...
(Date:7/3/2015)... ... ... The global failure analysis market is expected to reach $7,147.0 million by 2020, at ... grow at the highest CAGR of 8.46%; its growth is expected to be driven ... institutions for root cause analysis of failure. The market based on the geographic regions ...
(Date:7/2/2015)... ... ... have been used in countless labs for decades. In the past, people had to ... expected, this was a daunting and tiring process looking at endless data tables and charts. ... navigate the complex catalog structure. , Now thanks to FireflySci, scientists are throwing away those ...
Breaking Biology Technology:Emdeon to Acquire Altegra Health 2Emdeon to Acquire Altegra Health 3Emdeon to Acquire Altegra Health 4ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5New Cuvette E-Commerce Website Launched by FireflySci 2
... Ahmed Fazil Madison, Wis. - The 2006 ... has launched its first identity theft product, and has ... and three million customers after two years. , ,This probably ... plans to reach positive cash flow, but consider the total ...
... of Fresno in California's San Joaquin Valley is one of ... from grapes to livestock, from almonds to dairy products, and ... San Joaquin Valley these days is biofuel. , ,Like many ... recent visit are happy that demand for ethanol and biodiesel ...
... appears that Wisconsin has failed in its bid to lure a ... a maker of neural stem cell kits for researchers, apparently has ... it was spun out of the University of Georgia . ... likely that the company will remain in Georgia, despite an incentive ...
Cached Biology Technology:Identity theft start up has fast-track growth plans 2Identity theft start up has fast-track growth plans 3Kind approach to leveraging biofuels 2Kind approach to leveraging biofuels 3Georgia stem cell company likely to stay put 2
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., a ... by the United States Patent and Trademark Office (USPTO) ... process leverages TAKE Solutions, Clinical Accelerators to reduce the ... (when compared to standardization without the accelerators), thus reducing ... At the heart of the patented ...
(Date:6/24/2015)... 24, 2015 Biometry authentication provider KeyLemon ... password solution one face in. ... one face in, entering the expanding biometric authentication ... multifactor-authentication biometric answer to the password problem. With ... partnership with KeyLemon, one face in allows users ...
(Date:6/18/2015)... This report analyzes the worldwide markets for ... Segments, which includes Immunoassay Analyzers and Reagents: Enzyme Immunoassay ... Systems, and Nephelometric Immunoassay Systems. The report provides separate ... , Japan , Europe ... Latin America , and Rest of World. Annual ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... people with the genetic condition known as phenylketonuria (PKU), diet ... and instead get their daily dose of this key macronutrient ... it they must; deviating from this strict dietary regimen puts ... In the near future, fortunately, a better option may become ...
... are at increased risk for type 2 diabetes, Medical ... study of 50 people newly-diagnosed with schizophrenia or a ... 16 percent had either diabetes or an abnormal rate ... of the MCG Department of Psychiatry and Health Behavior. ...
... CRUZ, CA--A Cancer Genomics Browser developed by researchers at ... way to visualize and analyze data from studies aimed ... roots of the disease. The browser consists ... researchers find patterns in the huge amounts of clinical ...
Cached Biology News:UW-Madison study reveals new options for people with PKU 2UW-Madison study reveals new options for people with PKU 3Researchers discover link between schizophrenia and diabetes 2Cancer Genomics Browser gives cancer researchers a powerful new tool 2Cancer Genomics Browser gives cancer researchers a powerful new tool 3Cancer Genomics Browser gives cancer researchers a powerful new tool 4
... Supply, 1. 300 V, 400 mA, ... current modes.Single-unit increments in settings and ... submarine, mini vertical, and standard vertical ... and mini tank blotting applications. Category: ...
Mouse monoclonal [PRMT5-21] to PRMT5 ( Abpromise for all tested applications). entrezGeneID: 10419 SwissProtID: O14744...
B3-1...
Mouse TrkC Affinity Purified Polyclonal Ab...
Biology Products: